Why this innovator is passionate about uniting Texans in tech and venture

HOUSTON INNOVATORS PODCAST EPISODE 206

CS Freeland joins the Houston Innovators Podcast to discuss the Texas Venture Crawl on Oct. 6. Photo courtesy

This Friday, Texas innovators across the state will simultaneously show up to support each other, network with potential investors, and talk shop — and it's all thanks to one Austinite.

CS Freeland is organizing the second annual Texas Venture Crawl, which started last year in Austin to connect the ecosystem by way of casual conversations and social activity. This year, she's expanded to include eight cities in Texas across 12 venues. Houstonians can attend at the Ion at 5 pm on Friday, October 6.

"We thought it would be a couple of hundred of people, but it kind of went viral at the last minute," Freeland says on the Houston Innovators Podcast of last year's impact. And this year's new Houston presence is shaping up similarly with tickets close to being sold out.

Freeland also co-founded the Texas Venture Alliance, which launched in January. The nonprofit is the state’s largest venture capital network. The organization works to co-create and co-organize events and resources that create an ecosystem of startup support.

From Freeland's perspective, Texas has the potential to be a powerful region for startup, innovation, and venture capital.

"Silicon Valley is a big place to start a company and fund companies, but Silicon Valley is also just a region made up of cities," she says on the show. "I think if we thought of ourselves as a region and we worked together, we would be a really big force."

She's hoping to move the needle on that beginning with a casual happy hour with innovators across the state. And Houston gets a bit of a bonus event with Greentown Labs hosting its own happy hour in collaboration with the Texas Venture Crawl on Thursday, October 5.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”